Two Public Consultations are open at CONITEC to evaluate medications for the treatment of Follicular Lymphoma.
Both evaluations are under internal demand from the Department of Science, Technology and Innovation and the Economic-Industrial Health Complex (SECTICS), resulting from the update of the Ministry of Health's Follicular Lymphoma Diagnostic and Therapeutic Guidelines:
🔴 Rituximab monotherapy for the treatment of patients with asymptomatic follicular lymphoma, regardless of the initial stage
▶️ Link to participate: https://www.gov.br/participamaisbrasil/consulta-publica-conitec-sectics-n-15-2024-rituximabe
🔴 Lenalidomide in combination with rituximab for previously treated follicular lymphoma patients
▶️ Link to participate: https://www.gov.br/participamaisbrasil/consulta-publica-conitec-sectics-n-16-2024-lenalidomida-combinacao
Based on the Reports for Society, published in Participa + Brazil for each drug under evaluation, both rituximab and lenalidomide are approved by the National Health Surveillance Agency (Anvisa) and are recommended for adult patients with:
- CD20-positive, relapsed, or chemotherapy resistant low-grade B cell or follicular non-Hodgkin lymphoma;
- previously untreated, follicular, CD20-positive, B-cell non-Hodgkin lymphoma in combination with chemotherapy;
- Follicular lymphoma, as maintenance treatment, after responding to induction therapy.
Contribute your knowledge and share with other health professionals who can give their reports about such medications.
Together we can make a difference in the lives of many people.
